Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Pediatrics|January 24, 2007
Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukastDavid A Stempel, Denise T Kruzikas, Ranjani Manjunath
Epilepsy & Behavior : E&B|July 10, 2012
Patients' preferences for treatment outcomes of add-on antiepileptic drugs: a conjoint analysisRanjani Manjunath, Jui-Chen Yang, Alan B Ettinger
Managed Care (Langhorne, Pa.)|November 20, 2012
Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonistsJuliana Meyers, Sean Candrilli, Richard Allen, et al.
Epilepsy & Behavior : E&B|May 3, 2011
Risk factors for antiepileptic drug regimen change in patients with newly diagnosed epilepsyMarianne C Cunnington, David J Webb, Michael C Irizarry, et al.
Epilepsy & Behavior : E&B|January 8, 2009
Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsyRanjani Manjunath, Keith L Davis, Sean D Candrilli, et al.
Epilepsy Research|August 31, 2010
The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsySean D Candrilli, Ranjani Manjunath, Keith L Davis, et al.
Patient Preference and Adherence|May 21, 2013
Prospective, open-label trial measuring satisfaction and convenience of two formulations of lamotrigine in subjects with mood disordersMartha Sajatovic, Thomas R Thompson, Kevin Nanry, et al.
Epilepsy & Behavior : E&B|November 26, 2008
Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsyAlan B Ettinger, Ranjani Manjunath, Sean D Candrilli, et al.
Epilepsy & Behavior : E&B|June 14, 2014
The relationship of depression to antiepileptic drug adherence and quality of life in epilepsyAlan B Ettinger, Margaret B Good, Ranjani Manjunath, et al.
Disease Management : DM|August 28, 2007
The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigineMei Sheng Duh, Frederick Andermann, Pierre Emmanuel Paradis, et al.
Pageof 3